A Phase 2 interventional study of RSVPreF3 OA investigational vaccine (GSK3844766A) in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 10 sites in 2 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-29.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 33rd largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 2, and was the 16th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 21
First in 2013; this study’s year is marked. 2 started in 2020.
This study's enrollment of 126 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 642 across the 40 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nine different formulations of the RSVPreF3 OA investigational vaccine were tested in the parent study (NCT03814590). Based on safety and immunogenicity data from the parent study, RSVPreF3 OA investigational vaccine will be evaluated in further clinical research. Participants in selected groups will be invited to participate in this extension study. All participants who will be enrolled in the current extension study will receive the RSV investigational vaccine approximately 18 months after they received their respective dose-2 in the parent study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in one of the high dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group High Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by intramuscular (IM) injection in the non-dominant arm.
Biological: RSVPreF3 OA investigational vaccine (GSK3844766A)
Participants in one of the medium dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Medium Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
Biological: RSVPreF3 OA investigational vaccine (GSK3844766A)
Participants in one of the low dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Low Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
Biological: RSVPreF3 OA investigational vaccine (GSK3844766A)
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
Number of Participants With Any Solicited Administration Site Adverse Events (AEs)
Assessed solicited administration site AEs are erythema, pain and swelling. Any pain is defined as any pain regardless of intensity grade. Any injection site erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).
Time frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
Number of Participants With Any Solicited Systemic AEs
Assessed solicited systemic AE is fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity). Any is defined as occurrence of the symptom regardless of intensity grade or relation to study.
Time frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
Number of Participants With Any Unsolicited AEs
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to study vaccination.
Time frame: During the 30-day follow-up period post-vaccination (i.e., on the day of vaccination [Day 1] and 29 subsequent days)
Number of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccination
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination.
Time frame: From Day 1 up to 30 days post-vaccination (Day 31)
Number of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccination
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any is defined as the occurrence of any pIMD regardless of intensity grade or relation to study vaccination.
Time frame: From Day 1 up to 30 days post-vaccination (Day 31)
Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype A
Serological assays for the determination of functional antibodies against RSV-A are performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as Geometric Mean Titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).
Time frame: At 30 days post-vaccination (Day 31)
Humoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype B
Serological assays for the determination of functional antibodies against RSV-B are performed by neutralization assay. Anti RSV-B neutralizing antibody titers are given as GMTs and expressed as ED60.
Time frame: At 30 days post-vaccination (Day 31)
Humoral Immune Response in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations
The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect Enzyme-Linked Immunosorbent Assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).
Time frame: At 30 days post-vaccination (Day 31)
Frequency of RSVPreF3-specific Cluster of Differentiation 4+ (CD4+) T-cells Identified as Expressing at Least Two Markers
Among markers expressed are interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumour necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At 30 days post-vaccination (Day 31)
Number of Participants With Any SAEs, up the End of Follow-up Study Period (Month 6)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
Time frame: From Day 1 up to the end of follow-up period (Month 6)
Number of Participants Reporting pIMDs up to the End of Follow-up Study Period (Month 6)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From Day 1 up to the end of follow-up period (Month 6)
From a total of 126 participants enrolled in this study, 4 participants were withdrawn before vaccination. 122 participants received the study vaccination.
| Milestone | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Started | 40 | 39 | 43 |
| Completed | 39 | 39 | 43 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Consent withdrawal, not due to a (s)ae | 1 | 0 | 0 |
Assessed solicited administration site AEs are erythema, pain and swelling. Any pain is defined as any pain regardless of intensity grade. Any injection site erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).
| Participants | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Any erythema | 1 | 6 | 5 |
| Any pain | 21 | 23 | 26 |
| Any swelling | 0 | 2 | 4 |
Assessed solicited systemic AE is fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity). Any is defined as occurrence of the symptom regardless of intensity grade or relation to study.
| Participants | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Number of Participants With Any Solicited Systemic AEs | 1 | 1 | 4 |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to study vaccination.
| Participants | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Number of Participants With Any Unsolicited AEs | 5 | 11 | 12 |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination.
| Participants | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Number of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccination | 0 | 0 | 0 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any is defined as the occurrence of any pIMD regardless of intensity grade or relation to study vaccination.
| Participants | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Number of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccination | 0 | 0 | 0 |
Serological assays for the determination of functional antibodies against RSV-A are performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as Geometric Mean Titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).
| Titers | High Dose_AS01E Group |
|---|---|
| Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype A | 4394.9 (3191.3 to 6052.5) |
Serological assays for the determination of functional antibodies against RSV-B are performed by neutralization assay. Anti RSV-B neutralizing antibody titers are given as GMTs and expressed as ED60.
| Titers | High Dose_AS01E Group |
|---|---|
| Humoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype B | 6094.3 (4476.8 to 8296.4) |
The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect Enzyme-Linked Immunosorbent Assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).
| ELU/mL | High Dose_AS01E Group |
|---|---|
| Humoral Immune Response in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | 46276.5 (36821.3 to 58159.6) |
Among markers expressed are interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumour necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
| cells per million CD4+ T Cells | High Dose_AS01E Group |
|---|---|
| Frequency of RSVPreF3-specific Cluster of Differentiation 4+ (CD4+) T-cells Identified as Expressing at Least Two Markers | 1601 (1174 to 2541) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
| Participants | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Number of Participants With Any SAEs, up the End of Follow-up Study Period (Month 6) | 1 | 1 | 2 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Participants | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Number of Participants Reporting pIMDs up to the End of Follow-up Study Period (Month 6) | 0 | 0 | 0 |
Collected over Solicited AEs were collected during the 4-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to Month 6).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose_AS01E Group | 0/40 (0%) | 1/40 (2.5%) | 22/40 (55%) |
| Low Dose_AS01E Group | 0/39 (0%) | 1/39 (2.6%) | 25/39 (64.1%) |
| Medium Dose_AS01E Group | 0/43 (0%) | 2/43 (4.7%) | 29/43 (67.4%) |
| Event | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| DiverticulitisInfections and infestations | 0/40 | 1/39 | 0/43 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 | 0/39 | 0/43 |
| Limb traumatic amputationInjury, poisoning and procedural complications | 0/40 | 0/39 | 1/43 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/40 | 0/39 | 1/43 |
| Event | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group |
|---|---|---|---|
| Injection site painGeneral disorders | 21/40 | 23/39 | 26/43 |
| Injection site erythemaGeneral disorders | 1/40 | 6/39 | 5/43 |
| HeadacheNervous system disorders | 1/40 | 4/39 | 1/43 |
| Injection site swellingGeneral disorders | 0/40 | 2/39 | 4/43 |
| PyrexiaGeneral disorders | 1/40 | 1/39 | 4/43 |
| FatigueGeneral disorders | 1/40 | 1/39 | 3/43 |
| ChillsGeneral disorders | 0/40 | 2/39 | 2/43 |
| Influenza like illnessGeneral disorders | 0/40 | 2/39 | 2/43 |
| MalaiseGeneral disorders | 0/40 | 2/39 | 1/43 |
| Axillary painGeneral disorders | 0/40 | 1/39 | 0/43 |
| Age, Continuous(Years) | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group | Total |
|---|---|---|---|---|
| Mean | 68.3 ± 5.4 | 69.1 ± 5.3 | 66.6 ± 5.6 | 68.0 ± 5.5 |
| Sex: Female, Male(Participants) | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group | Total |
|---|---|---|---|---|
| Female | 27 | 21 | 24 | 72 |
| Male | 13 | 18 | 19 | 50 |
| Race/Ethnicity, Customized(Participants) | High Dose_AS01E Group | Low Dose_AS01E Group | Medium Dose_AS01E Group | Total |
|---|---|---|---|---|
| American Indian Or Alaska Native | 1 | 0 | 0 | 1 |
| Black Or African American | 1 | 2 | 1 | 4 |
| White | 38 | 37 | 42 | 117 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Dec 2020 to primary completion in Jun 2021, 5 months.
Results were first posted in Jun 2022, 1 year after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 5 months is below that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →